Studies how PSMA PET scans may predict outcomes in prostate cancer
Observes prostate cancer patients who had PSMA PET scans, comparing scan results with clinical scores.
Plain-language title generated from the registry record
Registry title: PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
Key facts
- Where
- Essen, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with biopsy-proven prostate cancer who had a PSMA PET scan for staging or re-staging and have at least 3 years of survival follow-up data.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Any stage of prostate cancer
- Earlier treatment
- Must have had a PSMA PET scan (any type) for staging or re-staging.
Main reasons for not taking part
- Neuroendocrine prostate cancer
- Spread (metastatic) cancer from a cancer other than prostate cancer
- Less than 3 years of overall survival follow-up data
Read by machine on 12 November 2026.
Where in Germany
- University Hospital EssenEssen, GermanyContact: Wolfgang P Fendler, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Essen
- Trial code
- NCT06320223
- Record updated
- 20 March 2024
- Original description
Background:Read full original descriptionShow less
PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer
Background:
PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.
Need:
Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.
Aim:
1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages
Inclusion:
* Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion:
* Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer
Inclusion:; Adult patients with; biopsy/histo proven prostate cancer who; underwent PSMA PET (any type); for staging or re-staging at any stage and who; have at least 3-year overall survival follow-up data available will be included consecutively; Exclusion:; Patients with neuroendocrine prostate cancer; Patients with metastasized or disseminated malignancy other than prostate cancer.